| Project/Area Number |
17K11223
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤原 浩 金沢大学, 医学系, 教授 (30252456)
大黒 多希子 金沢大学, 学際科学実験センター, 教授 (30767249)
保野 由紀子 金沢大学, 大学病院, その他 (80565416)
井口 雅史 金沢医科大学, 大学病院, 准教授 (90401918)
毎田 佳子 金沢大学, 保健学系, 教授 (20397219)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | タモキシフェン / 子宮内膜 / 卵巣過剰刺激 / 子宮内膜異常 / 乳癌 |
|---|
| Outline of Final Research Achievements |
１Background:Tamoxifen (TAM), the hormone therapy for premenopausal breast cancer patients, has been previously reported to have ovarian hyperstimulation. We have previously reported that among Japanese young women with breast cancer, ovarian stimulation by TAM is strongly present. In addition, the idea is that the endometrium under TAM administration is directly stimulated by TAM, which not only induces endometrial cancer but also induces a new pathological condition of infertility. 2 Purpose: Analyzing the mechanism of action of ovarian hyperstimulation and endometrium change by TAM. 3Method: Retrospective and prospective view of ovarian hyperstimulation and the thickening and abnormality (polyp,Swiss-cheeselike )of the endometrium.4Result:The incidence and pattern of ovarian hyperstimulation by TAM administration method (Gn-RHa combination, after chemotherapy) and age were clarified. It was clarified that endometrial abnormalities due to TAM administration appeared in almost half.
|
| Academic Significance and Societal Importance of the Research Achievements |
閉経前の乳癌患者に対するホルモン治療の第一選択であるタモキシフェン(TAM)には,高頻度で卵巣過剰刺激作用があること、またTAM投与方法や年齢により出現率やパターンが違うことが明らかになり、47歳未満、また、単独投与では50歳以上でも注意しなければならないことが分かった。また、TAM投与下の子宮内膜は、半数近くに肥厚を認め、TAMの直接作用による変化を受けていることがわかった。この変化は、年齢に関係なく、妊孕性温存が必要な若年にも影響を与えており、乳癌治療後の妊娠率低下の原因は卵巣機能低下に加えて子宮内膜胚受容機能低下も関わっていることが分かった。
|
